News Release – 2014 | News Release | Hisamitsu Pharmaceutical co.,inc.

2014.10.23: Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)

2014.10.20: Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis

2014.10.09: FY02/2015 Q2 Results Earnings Release Presentation

2014.10.02: Notice of Revision of Financial Forecast

2014.09.26: Noven Pharmaceuticals, Inc. press release :Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System)

2014.08.05: Notice of Dissolution of US Equity Method Affiliate Vivelle Ventures LLC (d/b/a Novogyne Pharmaceuticals)

2014.07.10: FY02/2015 Q1 Results Earnings Release Presentation

2014.07.02: Notification of the Noven Pharmaceuticals, Inc. assigns rights for Lithobid® (lithium carbonate tablets)

2014.06.20: Notification of approval of the additional indication for chronic pain of the transdermal long-acting pain relief patch FENTOS® TAPE (development code: HFT-290)

2014.05.29: Announcement of 2014 National Commendation for Invention “The Prize of the Commissioner of Japan PatentOffice” – For Invention of anti-inflammatory analgesic patch superior in percutaneous absorbability –

2014.05.13: 5th Medium-term Management Plan for FY2014-2018

2014.05.13: Notice Concerning the Establishment of the 5th Medium-term Management Plan

2014.05.07: Press Release related to the results of Phase II clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)

2014.04.24: Notification on the commencement of Phase I clinical trial of HP-3070 in the United States (a transdermal tape formulation for the treatment of schizophrenia)

2014.04.17: Noven Pharmaceuticals, Inc. press release :Noven announces settlement of LIDODERM® patent litigation

2014.04.10: FY02/2014 Q4 Results Earnings Release Presentation

2014.04.10: Announcement of Dividend of Surplus in the Fiscal Year Ended February 2014 (112th Fiscal Year)

2014.02.21: Notification of approval of additional ‘indication’ and ‘dosage and administration’ of the estradiol transdermal patch Estrana® Tape 0.72 mg

2014.02.05: Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal drug for the treatment of Parkinson’s disease)

2014.01.14: Noven Pharmaceuticals, Inc. press release :Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules

2014.01.09: FY02/2014 Q3 Results Earnings Release Presentation